The multisystem robotics platform will accelerate discovery of potential candidates for Novo Nordisk's peptide and large molecule therapeutics research, according to the company.

The platform will include automated and integrated cells for production, characterization, and functional analysis of thousands of biologic compounds every month. Also, it aims to cover the full range from small synthetic peptides to recombinantly expressed large proteins, and it will include chemical modification of the molecules.